Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
65°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
149.06
-3.19 (-2.10%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 29, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
47
48
Next >
Week In Review: Adlai Nortye Stages $97.5 Million US IPO On Nasdaq
September 30, 2023
While ANL's IPO dropped more than 25% on its first day, netting just under $60M, private placement made up the difference. Plus: Deals, financings, trials and approvals.
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs
September 30, 2023
The best drug stocks to buy now are shooting for the moon. These three trailblazers will land among the stars.
Via
InvestorPlace
3 Magnificent Dividend Stocks to Buy in October
September 30, 2023
These stocks come with great dividends and more.
Via
The Motley Fool
AbbVie's Promising Leap Towards Long-Term Growth: Analyst
September 29, 2023
Raymond James initiated coverage on AbbVie Inc (NYSE: ABBV) as the company looks beyond Humira's loss of exclusivity and has several levers to set up long-term growth.
Via
Benzinga
AbbVie's Leukemia Drug Falls Short In Late-Stage Study In Pretreated Blood Cancer Patients
September 29, 2023
AbbVie Inc (NASDAQ: ABBV) released data from its Phase 3 CANOVA study evaluating venetoclax (Venclexta/ Venclyxto) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory...
Via
Benzinga
What 4 Analyst Ratings Have To Say About AbbVie
September 29, 2023
Via
Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today
September 27, 2023
Via
Benzinga
AbbVie Unusual Options Activity
September 26, 2023
Via
Benzinga
How Is The Market Feeling About AbbVie?
September 25, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023
September 29, 2023
Via
Benzinga
Want $500 in Passive Income? Invest $3,500 Into These 3 Dividend Stocks and Wait 4 Years
September 29, 2023
A basket of passive income opportunities in oil and gas, renewable energy, and healthcare.
Via
The Motley Fool
Three Of Our Top Picks For Your Healthcare Portfolio
September 26, 2023
Amidst macro uncertainty, healthcare stocks should outperform.
Via
Talk Markets
This Is What Whales Are Betting On AbbVie
September 18, 2023
Via
Benzinga
Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today
September 15, 2023
Via
Benzinga
AbbVie Unusual Options Activity For September 13
September 13, 2023
Via
Benzinga
Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher
September 26, 2023
With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio.
Via
InvestorPlace
Clorox Pullback Presents a Chance to Clean Up on a 3.6% Dividend
September 26, 2023
The Clorox Company's 44% two-year plunge has created an opportunity to own a defensive stock with a shiny 3.6% dividend.
Via
MarketBeat
Argenx's 28% Surge & Promising Product Propel Investor Confidence
September 25, 2023
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
Via
MarketBeat
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
September 21, 2023
Many stocks have nosebleed valuations. But not these.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
September 21, 2023
Via
Benzinga
Only 7 Large-Cap Dividend Kings Yield Over 3%. Here's My Top Pick to Buy Now.
September 21, 2023
Dividend Kings are passive income powerhouses, but they aren't always a good value.
Via
The Motley Fool
Flee to Healthcare Stocks if Recession Rears its Head?
September 20, 2023
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke
September 19, 2023
The company is still figuring out how to gain share in a market topped by AbbVie.
Via
Investor's Business Daily
7 Safe and Steady Dividend Stocks to Buy for Volatile Time
September 19, 2023
Discover how these seven standout companies offer both security and growth potential in an uncertain financial landscape.
Via
InvestorPlace
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
September 19, 2023
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Exposures
Economy
Product Safety
The Top 7 Underrated Dividend Stocks Yielding 3% or More
September 19, 2023
Investors seeking dependable income and upside should buy these dividend stocks yielding 3% or more, the sooner the better
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
September 18, 2023
Via
Benzinga
2 Dividend Kings to Buy on the Dip and Hold Forever
September 15, 2023
Don't ignore these stocks just because the rest of the market is.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
September 14, 2023
Via
Benzinga
Why Is Immuno-Oncology Firm Harpoon Therapeutics Stock Trading Lower Today?
September 14, 2023
Harpoon Therapeutics Inc (NASDAQ: HARP) shares are trading lower after AbbVie Inc (NYSE: ABBV) chose not to exercise its exclusive license option within the Development and Option Agreement...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.